GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Jianke
Who Owns Jianke?
Jianke, officially Fangzhou Inc., is a major online B2C pharmacy and healthcare platform in China. Founded in 2009 by Xie Fangmin, it focuses on chronic disease management through technology, offering services like online consultations and e-prescriptions.
As of late 2024, Jianke boasts 49.2 million registered users and partners with 223,000 physicians, highlighting its significant reach. Its market capitalization was approximately $661 million with 1.34 billion shares as of July 25, 2025.
Understanding Jianke's ownership is key to grasping its strategic path and industry influence. This includes examining its founding stakes, early investors, major shareholders, board composition, and voting power dynamics. The company's Jianke BCG Matrix analysis is also influenced by these ownership structures.
Who Founded Jianke?
Jianke Company was established in 2009 by Xie Fangmin, who continues to hold significant influence as the founder, chairman, executive director, and CEO. While precise initial share distribution details are not public, Xie Fangmin's leadership roles underscore his foundational stake.
Founder's Role
Xie Fangmin is the founder and holds key executive positions, indicating substantial early ownership and ongoing control.
Pre-Listing Ownership
Before a business reorganization for listing, Guangdong Jianke was primarily owned by Mr. Su (55%) and Mr. Xie (45%).
Early Funding Rounds
The company secured a total of $280 million across three funding rounds in its early stages.
Series A Investment
The first funding round, a Series A, took place on January 28, 2016, with Crescent Point as an institutional investor.
Early Capital Strategy
Early institutional investments suggest a structured approach to capital acquisition, aligning with the founding team's long-term vision.
Founding Team's Vision
These initial agreements and investments were crucial in shaping the company's trajectory and the founder's strategic direction.
The early ownership structure of Jianke Company was significantly influenced by its founder, Xie Fangmin, and key early investors. While specific percentages from the very inception are not publicly detailed, the pre-listing reorganization revealed that Guangdong Jianke, the entity focused on online pharmacy operations via its mobile applications and website, was held with 55% by Mr. Su and 45% by Mr. Xie. This indicates a substantial initial stake for Mr. Xie, aligning with his role as founder and chief executive. The company's growth was supported by early funding, totaling $280 million raised over three rounds. The Series A funding, which occurred on January 28, 2016, saw participation from institutional investors like Crescent Point. These early financial commitments were instrumental in establishing the company's foundation and guiding its strategic development, reflecting a deliberate effort to secure capital and align stakeholders' interests. Understanding these early dynamics is key to grasping the Mission, Vision & Core Values of Jianke and its subsequent growth trajectory.
Complete Jianke Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
How Has Jianke’s Ownership Changed Over Time?
Jianke, operating as Fangzhou Inc. (06086.HK), has transitioned from a private entity to a publicly traded company, marking a significant shift in its ownership structure. This evolution has been fueled by substantial investment, with the company securing a total of $280 million across three funding rounds.
| Funding Round | Date | Amount Raised | Lead Investor | Other Investors |
|---|---|---|---|---|
| Series A | January 28, 2016 | Not specified | Not specified | Crescent Point |
| Series B | May 15, 2017 | Not specified | Not specified | Volcanics Venture, PGA Venture Partners |
| Series B | September 4, 2018 | $130 million | ShenZhen GTJA Investment Group | Hbm |
| 2020 Commitment | 2020 | $15 million | Not specified | FFP (now Peugeot Invest), Crescent Point |
As of July 25, 2025, Jianke boasts a market capitalization of $661 million, with 1.34 billion shares outstanding. The ownership landscape includes a group of Controlling Shareholders comprising Mr. Xie Fangmin, Mr. Zhou, and entities such as Fangrong Management Limited, Fangzhan Holdings L.P., Xingyu Holdings L.P., Celaeno Group Limited, Silica Brothers Corp., and Asia Tech Investments Ltd. This collective shareholding and voting proxy power significantly influences the company's direction, supporting its expansion in online retail pharmacy and comprehensive medical services. Understanding the Revenue Streams & Business Model of Jianke provides further context to the strategic decisions driven by these stakeholders.
Key Ownership Details
Jianke's ownership has evolved through significant funding rounds, attracting institutional capital. The company is now publicly traded, with a defined group of controlling shareholders.
- Total funding raised: $280 million
- Largest funding round: $130 million (Series B, September 4, 2018)
- Current market capitalization: $661 million (as of July 25, 2025)
- Number of shares outstanding: 1.34 billion (as of July 25, 2025)
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
Who Sits on Jianke’s Board?
The board of directors for Fangzhou Inc., also known as Jianke Company, is composed of both executive and non-executive members. This structure ensures a blend of internal operational knowledge and external oversight, crucial for effective corporate governance.
| Name | Role | Affiliation/Focus |
|---|---|---|
| Xie Fangmin | Founder, Chairman, Executive Director, CEO | Overall leadership and strategic direction |
| Zhou Feng | Executive Director, Chief Strategy Officer | Strategy, operations, investment, financing |
| Zou Yuming | Executive Director, Chief Financial Officer | Corporate finance, financial management |
| David McKee Hand | Non-executive Director | Represents Crescent Point, an early institutional investor |
| Wang Haizhong | Independent Non-executive Director | Chairs the Audit Committee |
| Zhu Xiaolu | Independent Non-executive Director | Chairs the Remuneration Committee |
| Kang Wei | Independent Non-executive Director | Chairs the Nomination Committee |
The ownership structure of Jianke Company indicates concentrated control, with Mr. Xie and Mr. Zhou, along with associated entities, identified as a group of Controlling Shareholders. This concentration of voting power, likely through shareholding and voting proxies, suggests their significant influence over the company's strategic decisions and future direction. While the specific voting rights per share are not detailed, this group's position implies a strong ability to shape the company's trajectory, a key aspect of understanding Jianke Company ownership.
Understanding Jianke Company's Governance
The board composition of Jianke Company reflects a commitment to diverse expertise. Independent directors play a vital role in ensuring accountability and strategic alignment.
- Founder's continued leadership is evident.
- Executive directors manage core operations.
- Non-executive directors provide external perspective.
- Independent directors ensure objective oversight.
- Understanding the Growth Strategy of Jianke is aided by board structure.
Jianke Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
What Recent Changes Have Shaped Jianke’s Ownership Landscape?
In recent years, Jianke, operating under the name Fangzhou Inc. (06086.HK), has significantly expanded its presence in China's online healthcare sector. The company has focused on chronic disease management, serving a substantial user base and collaborating with a large network of physicians.
| Metric | Value (as of Dec 31, 2024) | Significance |
|---|---|---|
| Registered Users | 49.2 million | Indicates broad market reach and user engagement. |
| Collaborating Physicians | 223,000 | Highlights extensive network and service capability. |
A pivotal development for Fangzhou Inc. occurred on July 21, 2025, with the signing of a Memorandum of Understanding with Novo Nordisk. This partnership aims to create a new health management ecosystem, specifically targeting serious chronic conditions such as diabetes and obesity. The collaboration is set to integrate Fangzhou's advanced AI application services, innovative treatment approaches, and pharmaceutical services, aligning with the growing trend of digital health solutions in China.
Strategic Partnership
The collaboration with Novo Nordisk signifies a strategic move to enhance chronic disease management services. This partnership is expected to leverage AI and innovative treatments for conditions like diabetes and obesity.
Market Growth Trends
China's pharmaceutical market is projected to reach 1.4 trillion yuan by 2025, with digital health and online pharmacies playing increasingly disruptive roles. This growth is driven by innovation and a focus on personalized healthcare.
Regulatory Environment
Since 2019, China has permitted the online sale of prescription drugs, fostering the growth of online pharmacies. This regulatory shift, coupled with the pandemic's impact, has accelerated the adoption of telepharmacy and AI-driven solutions.
Hong Kong IPO Market
The Hong Kong IPO market is showing signs of recovery, with an estimated 20 to 30 Chinese companies anticipated to list in 2025. This trend could influence future funding and ownership structures for companies like Fangzhou Inc.
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Brief History of Jianke Company?
- What is Competitive Landscape of Jianke Company?
- What is Growth Strategy and Future Prospects of Jianke Company?
- How Does Jianke Company Work?
- What is Sales and Marketing Strategy of Jianke Company?
- What are Mission Vision & Core Values of Jianke Company?
- What is Customer Demographics and Target Market of Jianke Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.